0001209191-23-021413.txt : 20230328 0001209191-23-021413.hdr.sgml : 20230328 20230328164702 ACCESSION NUMBER: 0001209191-23-021413 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230324 FILED AS OF DATE: 20230328 DATE AS OF CHANGE: 20230328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yanchik Connealy Pamela CENTRAL INDEX KEY: 0001796310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 23770215 MAIL ADDRESS: STREET 1: 320 W 37TH STREET, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-24 0 0001782223 Pyxis Oncology, Inc. PYXS 0001796310 Yanchik Connealy Pamela C/O PYXIS ONCOLOGY, INC. 150 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 CFO and COO 0 Common Stock 2023-03-24 4 A 0 209803 0.00 A 594313 D Stock Option (Right to buy) 8.71 2023-03-24 4 D 0 322265 D 2031-07-30 Common Stock 322265 0 D Stock Option (Right to buy) 8.71 2023-03-24 4 D 0 10304 D 2031-09-14 Common Stock 10304 0 D Stock Option (Right to buy) 2.21 2023-03-24 4 A 0 322265 A 2031-07-30 Common Stock 322265 322265 D Stock Option (Right to buy) 2.21 2023-03-24 4 A 0 10304 A 2031-09-14 Common Stock 10304 10304 D Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. These stock options vested 25% on the first anniversary of the July 31, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. /s/ Pamela Connealy 2023-03-28